Corrections to “Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies”

Naidoo, Jarushka; Page, David B.; Li, B. T.; Connell, Louise C.; Schindler, Katja; Lacouture, Mario E.; Postow, Michael A.; Wolchok, J. D.

doi:10.1093/annonc/mdw141

Cited by 154 publications

(89 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…38 Meanwhile, Nivolumab and Pembrolizumab are the recently approved immune checkpoint blockades for treating advanced non-small cell lung cancer after failure of traditional chemotherapy or not. 3 Several clinical studies 17,18,20,39 assessed relationship between NLR and immunotherapy, and some of them 17,18,20 argued that NLR could serve as a predictive factor while other found negative results. 39 Could NLR be a candidate for predicating prognosis of Nivolumab in NSCLC?…”

Section: Discussionmentioning

confidence: 99%

“…3 Several clinical studies 17,18,20,39 assessed relationship between NLR and immunotherapy, and some of them 17,18,20 argued that NLR could serve as a predictive factor while other found negative results. 39 Could NLR be a candidate for predicating prognosis of Nivolumab in NSCLC? How to feasibly and reliably determine NSCLC population who can gain a better benefit from Nivolumab?…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies

Cao

et al. 2018

OncoImmunology

View full text Add to dashboard Cite

Objective: Nivolumab has been used for treating non-small cell lung cancer (NSCLC) worldwide. Whether neutrophil-lymphocyte ratio (NLR) can predict the prognosis of NSCLC treated with Nivolumab is still under debate. This meta-analysis was to assess the significance of NLR as a predictive factor in NSCLC patients receiving Nivolumab.Methods: Databases including PubMed, Embase, and the Cochrane library were searched to identify eligible studies evaluating the role of NLR in predicting prognosis of NSCLC treated with Nivolumab until March 2018 without language restrictions. The meta-analysis was performed using hazard ratio (HR) of progression free survival (PFS) and overall survival (OS) in NSCLC patients with various NLR.Results: A total of 14 retrospective studies consisting of 1225 NSCLC patients were included. The combined results showed that relatively higher baseline NLR was associated with poor PFS (HR = 1.44; 95% confidence interval (CI):1.18–1.77; p < 0.05) and OS (HR = 1.75; 95% CI: 1.33–2.30; p < 0.05) after treatment of Nivolumab. Subgroup analysis suggested that NLR ≥ 5 was more reliable for PFS (HR = 1.73; 95%CI: 1.14, 2.62; p < 0.05) and OS (HR = 1.76; 95%CI: 1.47, 2.10; p < 0.05). In addition, post-treatment NLR also had predictive roles for PFS (HR = 3.17; 95%CI: 1.48, 6.82; p < 0.05) and OS (HR = 2.26; 95%CI: 1.05, 4.86; p < 0.05).Conclusion: Our findings suggest that NLR can be used as a prognostic biomarker for NSCLC treating with Nivolumab, and the recommended cutoff value of NLR is 5.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies

Cao

et al. 2018

OncoImmunology

View full text Add to dashboard Cite

show abstract

“…Often radiographic findings such as stranding of the pancreas are not present, but amylase and lipase can be elevated. Although the routine evaluation of amylase and lipase levels in asymptomatic patients is not recommended outside of a clinical trial, symptomatic patients should have their amylase and lipase levels drawn for diagnostic clarification [18]. Treatment of immune-related pancreatitis is based on the severity of symptoms.…”

Section: ©Alphamed Press 2016mentioning

confidence: 99%

Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents

et al. 2016

View full text Add to dashboard Cite

Immune checkpoint inhibitors have emerged as a mainstay of melanoma therapy and are playing an increasingly important role in the treatment of other tumor types. The clinical benefit afforded by these treatments can be accompanied by a unique spectrum of adverse events, called immune-related adverse events (irAEs), which reflect the drug's immune-based mechanism of action. IrAEs typically originate in the skin, gastrointestinal tract, liver, and endocrine system, although other organ systems may also be affected.This article provides an overview of irAEs associated with anti-programmed death-1 (anti-PD-1) antibodies (nivolumab and pembrolizumab) as monotherapy or in combination with anti-cytotoxic T-lymphocyte antigen-4 inhibition (ipilimumab), followed by a discussion of irAEs of special clinical interest based on the potential for morbidity, frequent steroid use, and inpatient admission.We review clinical trial data and provide recommendations on how to manage irAEs associated with anti-PD-1 agents based on clinical experience and established management guidelines. We further illustrate the practical considerations of managing irAEs by presenting three cases of immune-related toxicity in melanoma patients treated with nivolumab or pembrolizumab. A better understanding of the identification and management of irAEs will help inform health care providers about the risks associated with anti-PD-1 treatment, to ensure the safe and appropriate use of these important new treatments. The Oncologist 2016;21:1230-1240 Implications for Practice: Immune checkpoint inhibitors have demonstrated significant clinical benefit in advanced melanoma and other tumor types.These treatments are associated with immune-related adverse events (irAEs), which most commonly affect the skin and gastrointestinal tract, and, to a lesser extent, the liver, endocrine system, and other organs. This review focuses on the management of irAEs after treatment with anti-programmed death-1 (anti-PD-1) antibodies (nivolumab or pembrolizumab) as monotherapy or in combination with anti-cytotoxic T-lymphocyte antigen-4 inhibition (ipilimumab) in patients with advanced melanoma. A better understanding of the management of irAEs will help ensure the safe and appropriate use of anti-PD-1 agents in melanoma and other tumor types.

show abstract

“…As a result of generalized immune activation, immune-related adverse events affecting practically every tissue have been described. 73 These side effects commonly involve the skin (vitiligo, rash, pruritus), gastrointestinal tract (diarrhea, colitis), liver (hepatitis) and endocrine glands (hypophysitis, thyroiditis, adrenal insufficiency).…”

Section: Toxicity Of Immune Checkpoint Inhibitionmentioning

confidence: 99%

The emerging role of immune checkpoint inhibition in malignant lymphoma

et al. 2016

View full text Add to dashboard Cite

Corrections to “Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies”

Cited by 154 publications

References 0 publications

A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies

A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies

Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents

The emerging role of immune checkpoint inhibition in malignant lymphoma

Contact Info

Product

Resources

About